{"id":"oxycodone-naloxone-controlled-release","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Constipation"},{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Dizziness"},{"rate":"15-20","effect":"Somnolence"},{"rate":"10-15","effect":"Vomiting"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL3249799","moleculeType":"Small molecule","molecularWeight":"327.38"},"_fixedAt":"2026-03-30T18:38:42.916824","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxycodone is a mu-opioid receptor agonist that binds to opioid receptors in the central nervous system to produce analgesia. Naloxone, an opioid antagonist, is included to discourage abuse by blocking opioid effects if the tablet is crushed or dissolved, though naloxone has minimal systemic effect when taken orally as intended. The combination aims to maintain pain control while reducing misuse liability.","oneSentence":"Oxycodone/naloxone is a controlled-release opioid analgesic combined with an opioid antagonist designed to provide pain relief while reducing abuse potential.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:08.322Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe chronic pain requiring continuous opioid therapy"}]},"_fixedFields":["modality→Biologic"],"trialDetails":[{"nctId":"NCT05389813","phase":"PHASE2, PHASE3","title":"Comparison Between Oxycodone and Pregabalin as Preemptive Analgesia","status":"UNKNOWN","sponsor":"An-Najah National University","startDate":"2021-08-15","conditions":"Anesthesia","enrollment":150},{"nctId":"NCT03768466","phase":"PHASE4","title":"Efficacy and Safety of Oxycodone/Naloxone (Targin®) in Persistent Moderate to Severe Low Back Pain Following NSAIDs Treatment","status":"COMPLETED","sponsor":"Mundipharma Korea Ltd","startDate":"2018-11-21","conditions":"Low Back Pain","enrollment":123},{"nctId":"NCT00513656","phase":"PHASE2","title":"A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2007-09","conditions":"Cancer, Pain, Constipation","enrollment":230},{"nctId":"NCT01197261","phase":"PHASE2","title":"OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2010-09","conditions":"Interstitial Cystitis, Painful Bladder Syndrome, Pain","enrollment":120},{"nctId":"NCT01971632","phase":"PHASE3","title":"A Randomised, Double Blind, Placebo and Active Controlled, Double Dummy,Parallel Group Study to Determine the Safety and Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Subjects With Moderate to Severe, Chronic Nonmalignant Pain","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2005-01","conditions":"Subjects With Moderate to Severe, Chronic Nonmalignant Pain","enrollment":463},{"nctId":"NCT01112644","phase":"PHASE3","title":"Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2010-04","conditions":"Moderate to Severe Idiopathic RLS With Daytime Symptoms","enrollment":205},{"nctId":"NCT02680847","phase":"PHASE4","title":"Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain","status":"TERMINATED","sponsor":"Pfizer","startDate":"2016-01-21","conditions":"Moderate-severe Pain","enrollment":32},{"nctId":"NCT00679614","phase":"PHASE3","title":"Effect of Combined Use of Naloxone and Tramacet on Postop Analgesia in Elderly Patients Having Joint Replacement Surgery","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2007-12-17","conditions":"Hip Arthroplasty, Knee Arthroplasty, Spinal Anesthesia","enrollment":45},{"nctId":"NCT01571362","phase":"PHASE3","title":"A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-06","conditions":"Chronic Pain, Low Back Pain, Analgesia","enrollment":410},{"nctId":"NCT02307305","phase":"PHASE2","title":"Does Duloxetine Reduce Chronic Pain After Total Knee Arthroplasty?","status":"UNKNOWN","sponsor":"Hanyang University Seoul Hospital","startDate":"2014-08","conditions":"Neuropathic Pain","enrollment":168},{"nctId":"NCT01358526","phase":"PHASE3","title":"Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2011-05","conditions":"Low Back Pain","enrollment":1095},{"nctId":"NCT01014559","phase":"PHASE3","title":"Efficacy of Oxycodone/Naloxone(OXN), Versus Oxycodone (OXY), for the Reduction of Intensity of Opioid-induced Constipation in Pain Patients","status":"TERMINATED","sponsor":"Mundipharma SAS","startDate":"2010-02","conditions":"Constipation, Pain","enrollment":225},{"nctId":"NCT01427283","phase":"PHASE3","title":"A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2011-08","conditions":"Low Back Pain","enrollment":450},{"nctId":"NCT01427270","phase":"PHASE3","title":"Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2011-08","conditions":"Low Back Pain","enrollment":455},{"nctId":"NCT01439100","phase":"PHASE3","title":"A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2011-10","conditions":"Parkinson's Disease With Severe Pain","enrollment":172},{"nctId":"NCT00944697","phase":"PHASE2","title":"A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2009-07","conditions":"Moderate to Severe Pain Due to Diabetic Polyneuropathy","enrollment":98}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TARGINIQ ER"],"phase":"phase_3","status":"active","brandName":"Oxycodone/Naloxone controlled-release","genericName":"Oxycodone/Naloxone controlled-release","companyName":"Purdue Pharma LP","companyId":"purdue-pharma-lp","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxycodone/naloxone is a controlled-release opioid analgesic combined with an opioid antagonist designed to provide pain relief while reducing abuse potential. Used for Moderate to severe chronic pain requiring continuous opioid therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}